require no small amount of effort and the 'targets' often change or 'evaporate' before the drug companies can realize an ROI on all that work (e.g. SARS, and MERS). But, from our perspective, who wouldn't want a simple to take, relatively inexpensive and easily accessible pill? As the article says, however, they shouldn't be viewed in a 'binary' sense wrt vaccinations...need to use all the tools to gain the upper hand here.
For me, with my personal experiences and access to people 'in the business'...I'm more trusting in the protocols we have, which goes to the actions taken for vaccines and mitigation efforts. I'm also very pleased to hear about progress on those those treatments we're discussing...can't wait for some announcements.